Accelerating mRNA-based therapies

A new vaccine technology based on mRNA is being tested in human clinical trials, accelerated by the SARS-Cov-2 global pandemic. mRNA-based therapeutics for a range of other conditions, from cystic fibrosis to cancer, are also entering early stage clinical trials. As mRNA production rapidly scales up, the critical need for a highly scalable mRNA purification technology has also emerged.

Our Thermo Scientific™ POROS™ Oligo (dT)25 affinity resin is tailor made for scalable mRNA purification. The mRNA sticks to the resin and impurities are washed away. This whitepaper examines the need for highly scalable mRNA production, and then explores the affinity resin’s advantages over other mRNA purification techniques.

Complete the short form below to download the full white paper.

(*Indicates a mandatory field)